Advertisement
Screener

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Increase (Decrease) in Accrued Taxes Payable

2.8 / 5 stars · 68/120 Roast Me

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Increase (Decrease) in Accrued Taxes Payable

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Increase (Decrease) in Accrued Taxes Payable of -$1.80 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-14.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedTaxesPayable · last filed 2017-02-14

  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in accrued taxes payable for the quarter ending 2016-12-31 was $3.87M.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in accrued taxes payable for the quarter ending 2016-09-24 was -$2.60M, a 154.20% decline year-over-year.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in accrued taxes payable for the quarter ending 2016-06-25 was $10.57M, a 24.16% decline year-over-year.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in accrued taxes payable for the quarter ending 2016-03-26 was -$13.65M.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in accrued taxes payable for fiscal 2016 was -$1.80M.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in accrued taxes payable for fiscal 2015 was -$3.91M.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in accrued taxes payable for fiscal 2014 was -$7.09M.
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC. increase (decrease) in accrued taxes payable for fiscal 2013 was -$3.05M, a 231.02% decline from fiscal 2012.
Period endIncrease (Decrease) in Accrued Taxes Payable 3 monthIncrease (Decrease) in Accrued Taxes Payable 6 monthIncrease (Decrease) in Accrued Taxes Payable 9 monthIncrease (Decrease) in Accrued Taxes Payable 12 month
2016-12-31$3.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14
$1.27M
derived: sum of 2 quarters · filed 2017-02-14
$11.85M
derived: sum of 3 quarters · filed 2017-02-14
-$1.80M
10-K · filed 2017-02-14
2016-09-24-$2.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02
$7.98M
derived: sum of 2 quarters · filed 2016-11-02
-$5.67M
10-Q · filed 2016-11-02
-$7.67M
derived: sum of 4 quarters · filed 2017-02-14
2016-06-25$10.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
-$3.08M
10-Q · filed 2016-08-03
-$5.08M
derived: sum of 3 quarters · filed 2017-02-14
-$285.00K
derived: sum of 4 quarters · filed 2017-02-14
2016-03-26-$13.65M
10-Q · filed 2016-05-04
-$15.65M
derived: sum of 2 quarters · filed 2017-02-14
-$10.86M
derived: sum of 3 quarters · filed 2017-02-14
$3.08M
derived: sum of 4 quarters · filed 2017-02-14
2015-12-26-$2.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14
$2.79M
derived: sum of 2 quarters · filed 2017-02-14
$16.73M
derived: sum of 3 quarters · filed 2017-02-14
-$3.91M
10-K · filed 2017-02-14
2015-09-26$4.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02
$18.73M
derived: sum of 2 quarters · filed 2016-11-02
-$1.91M
10-Q · filed 2016-11-02
-$5.04M
derived: sum of 4 quarters · filed 2017-02-14
2015-06-27$13.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
-$6.70M
10-Q · filed 2016-08-03
-$9.83M
derived: sum of 3 quarters · filed 2017-02-14
-$6.98M
derived: sum of 4 quarters · filed 2017-02-14
2015-03-28-$20.64M
10-Q · filed 2016-05-04
-$23.78M
derived: sum of 2 quarters · filed 2017-02-14
-$20.93M
derived: sum of 3 quarters · filed 2017-02-14
-$11.23M
derived: sum of 4 quarters · filed 2017-02-14
2014-12-27-$3.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14
-$288.00K
derived: sum of 2 quarters · filed 2017-02-14
$9.41M
derived: sum of 3 quarters · filed 2017-02-14
-$7.09M
10-K · filed 2017-02-14
2014-09-27$2.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04
$12.54M
derived: sum of 2 quarters · filed 2015-11-04
-$3.95M
10-Q · filed 2015-11-04
$2.55M
derived: sum of 4 quarters · filed 2016-02-12
2014-06-28$9.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30
-$6.80M
10-Q · filed 2015-07-30
-$299.00K
derived: sum of 3 quarters · filed 2016-02-12
-$5.56M
derived: sum of 4 quarters · filed 2016-02-12
2014-03-29-$16.50M
10-Q · filed 2015-04-30
-$9.99M
derived: sum of 2 quarters · filed 2016-02-12
-$15.26M
derived: sum of 3 quarters · filed 2016-02-12
-$12.61M
derived: sum of 4 quarters · filed 2016-02-12
2013-12-28$6.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12
$1.24M
derived: sum of 2 quarters · filed 2016-02-12
$3.88M
derived: sum of 3 quarters · filed 2016-02-12
-$3.05M
10-K · filed 2016-02-12
2013-09-28-$5.26M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30
-$2.62M
derived: sum of 2 quarters · filed 2014-10-30
-$9.56M
10-Q · filed 2014-10-30
-$14.55M
derived: sum of 4 quarters · filed 2015-02-17
2013-06-29$2.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$4.29M
10-Q · filed 2014-08-07
-$9.28M
derived: sum of 3 quarters · filed 2015-02-17
-$4.70M
derived: sum of 4 quarters · filed 2015-02-17
2013-03-30-$6.94M
10-Q · filed 2014-04-30
-$11.93M
derived: sum of 2 quarters · filed 2015-02-17
-$7.34M
derived: sum of 3 quarters · filed 2015-02-17
$2.71M
derived: sum of 4 quarters · filed 2015-02-17
2012-12-29-$4.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17
-$406.00K
derived: sum of 2 quarters · filed 2015-02-17
$9.65M
derived: sum of 3 quarters · filed 2015-02-17
$2.33M
10-K · filed 2015-02-17
2012-09-29$4.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30
$14.64M
derived: sum of 2 quarters · filed 2013-10-30
$7.32M
10-Q · filed 2013-10-30
$14.74M
derived: sum of 4 quarters · filed 2014-02-25
2012-06-30$10.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31
$2.74M
10-Q · filed 2013-07-31
$10.15M
derived: sum of 3 quarters · filed 2014-02-25
$13.23M
derived: sum of 4 quarters · filed 2014-02-25
2012-03-31-$7.32M
10-Q · filed 2013-05-08
$94.00K
derived: sum of 2 quarters · filed 2014-02-25
$3.17M
derived: sum of 3 quarters · filed 2014-02-25
$2.26M
derived: sum of 4 quarters · filed 2014-02-25
2011-12-31$7.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
$10.49M
derived: sum of 2 quarters · filed 2014-02-25
$9.58M
derived: sum of 3 quarters · filed 2014-02-25
-$13.78M
10-K · filed 2014-02-25
2011-09-24$3.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01
$2.17M
derived: sum of 2 quarters · filed 2012-11-01
-$21.20M
10-Q · filed 2012-11-01
2011-06-25-$909.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07
-$24.27M
10-Q · filed 2012-08-07
2011-03-26-$23.36M
10-Q · filed 2012-05-04
2010-12-25$13.09M
10-K · filed 2013-02-27
2009-12-26-$15.10M
10-K · filed 2012-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14
Absci Corp (ABSI)United States$1.775B-14.92
OmniAb, Inc. (OABI)United States$0.698B-8.05
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71